title: Myeloproliferative neoplasms.
abstract: The myeloproliferative neoplasms that are associated with the JAK2 mutation are a heterogeneous group of disorders. The additional mutations that result in the clinical phenotype are still the subject of research. As more than one mutation is involved, and as JAK2 has a necessary physiological role (unlike BCR-ABL), the development of targeted therapy remains a challenge. Although new drugs are being developed, treatment at present is predominantly with agents that have been in use for many years. An understanding of the need to control the thrombotic risk has, however, led to improved survival rates such that ET and PV can be seen as chronic diseases.
authors.affiliation: Department of Haematology, University Hospital Southampton. UK.
authors.forename: Amy
authors.initials: A
authors.lastname: Publicover
authors.forename: Patrick
authors.initials: P
authors.lastname: Medd
mesh_terms: D006400:Hematocrit; D006801:Humans; D053614:Janus Kinase 2 / Q000235:genetics*; D009154:Mutation; D011087:Polycythemia Vera / Q000175:diagnosis* / Q000235:genetics / Q000628:therapy; D055728:Primary Myelofibrosis / Q000175:diagnosis* / Q000235:genetics / Q000628:therapy; D011379:Prognosis; D013920:Thrombocythemia, Essential / Q000175:diagnosis* / Q000188:drug therapy / Q000235:genetics
chemical_list: C507924:JAK2 protein, human; D053614:Janus Kinase 2
keywords: JAK2; myelofibrosis; myeloproliferative; polycythaemia; thrombocytosis